Citius Oncology, Stock Performance
| CTOR Stock | 0.94 0.06 6.00% |
The firm shows a Beta (market volatility) of 1.97, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Citius Oncology, will likely underperform. At this point, Citius Oncology, has a negative expected return of -0.79%. Please make sure to confirm Citius Oncology,'s treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Citius Oncology, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Citius Oncology, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Citius |
Citius Oncology, Relative Risk vs. Return Landscape
If you would invest 177.00 in Citius Oncology, on August 30, 2024 and sell it today you would lose (83.00) from holding Citius Oncology, or give up 46.89% of portfolio value over 90 days. Citius Oncology, is currently does not generate positive expected returns and assumes 6.5356% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Citius, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Citius Oncology, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Citius Oncology,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Citius Oncology,, and traders can use it to determine the average amount a Citius Oncology,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1214
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CTOR |
Estimated Market Risk
| 6.54 actual daily | 58 58% of assets are less volatile |
Expected Return
| -0.79 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Citius Oncology, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Citius Oncology, by adding Citius Oncology, to a well-diversified portfolio.
Citius Oncology, Fundamentals Growth
Citius Stock prices reflect investors' perceptions of the future prospects and financial health of Citius Oncology,, and Citius Oncology, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Citius Stock performance.
| Current Valuation | 116.23 M | ||||
| Shares Outstanding | 2 M | ||||
| Price To Book | 4.55 X | ||||
About Citius Oncology, Performance
Assessing Citius Oncology,'s fundamental ratios provides investors with valuable insights into Citius Oncology,'s financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Citius Oncology, is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Citius Oncology, performance evaluation
Checking the ongoing alerts about Citius Oncology, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Citius Oncology, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Citius Oncology, generated a negative expected return over the last 90 days | |
| Citius Oncology, has high historical volatility and very poor performance | |
| Citius Oncology, has some characteristics of a very speculative penny stock | |
| Citius Oncology, was previously known as TenX Keane Acquisition and was traded on NASDAQ Exchange under the symbol TENK. | |
| Citius Oncology, has a very weak financial position based on the latest SEC disclosures |
- Analyzing Citius Oncology,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Citius Oncology,'s stock is overvalued or undervalued compared to its peers.
- Examining Citius Oncology,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Citius Oncology,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Citius Oncology,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Citius Oncology,'s stock. These opinions can provide insight into Citius Oncology,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.